See the DrugPatentWatch profile for cosentyx

FDA-Approved Drugs for Psoriatic Arthritis: Beyond Cosentyx

Psoriatic arthritis (PsA) is a chronic autoimmune disease that affects millions of people worldwide. It is characterized by inflammation in the joints and skin, leading to pain, stiffness, and swelling. While there is no cure for PsA, various treatments are available to manage its symptoms and prevent joint damage. One of the most popular biologics for PsA is Cosentyx (secukinumab), a human interleukin-17A antagonist. However, there are other FDA-approved drugs for PsA that can be effective for patients who do not respond to Cosentyx or experience adverse effects.

What are the FDA-Approved Drugs for Psoriatic Arthritis?

1. Humira (Adalimumab): Humira is a tumor necrosis factor (TNF) blocker that has been approved for PsA since 2005. It works by blocking the action of TNF, a protein that promotes inflammation.

"Humira has been a game-changer for many patients with PsA, providing significant relief from symptoms and improving quality of life." - Dr. Arthur Kavanaugh, Professor of Medicine at the University of California, San Diego

2. Enbrel (Etanercept): Enbrel is another TNF blocker that has been approved for PsA since 2004. It works by binding to TNF and preventing it from activating inflammatory pathways.

"Enbrel has been shown to be effective in reducing joint inflammation and improving physical function in patients with PsA." - Dr. Philip Mease, Professor of Medicine at the University of Washington

3. Remicade (Infliximab): Remicade is a TNF blocker that has been approved for PsA since 2003. It works by binding to TNF and preventing it from activating inflammatory pathways.

"Remicade has been used to treat a wide range of autoimmune diseases, including PsA, and has been shown to be effective in reducing symptoms and improving quality of life." - Dr. Mark Genovese, Professor of Medicine at the University of Colorado

4. Orencia (Abatacept): Orencia is a selective costimulation modulator that has been approved for PsA since 2009. It works by blocking the action of CD28, a protein that promotes T-cell activation.

"Orencia has been shown to be effective in reducing joint inflammation and improving physical function in patients with PsA." - Dr. Philip Mease, Professor of Medicine at the University of Washington

5. Stelara (Ustekinumab): Stelara is a monoclonal antibody that has been approved for PsA since 2009. It works by blocking the action of interleukin-12 and interleukin-23, two proteins that promote inflammation.

"Stelara has been shown to be effective in reducing symptoms and improving quality of life in patients with PsA." - Dr. Mark Genovese, Professor of Medicine at the University of Colorado

6. Cimzia (Certolizumab Pegol): Cimzia is a TNF blocker that has been approved for PsA since 2009. It works by binding to TNF and preventing it from activating inflammatory pathways.

"Cimzia has been shown to be effective in reducing joint inflammation and improving physical function in patients with PsA." - Dr. Philip Mease, Professor of Medicine at the University of Washington

7. Taltz (Ixekizumab): Taltz is a monoclonal antibody that has been approved for PsA since 2016. It works by blocking the action of interleukin-17A, a protein that promotes inflammation.

"Taltz has been shown to be effective in reducing symptoms and improving quality of life in patients with PsA." - Dr. Mark Genovese, Professor of Medicine at the University of Colorado

8. Ilaris (Canakinumab): Ilaris is a monoclonal antibody that has been approved for PsA since 2010. It works by blocking the action of interleukin-1 beta, a protein that promotes inflammation.

"Ilaris has been shown to be effective in reducing symptoms and improving quality of life in patients with PsA." - Dr. Philip Mease, Professor of Medicine at the University of Washington

What are the Key Takeaways?

* There are several FDA-approved drugs for PsA beyond Cosentyx, including Humira, Enbrel, Remicade, Orencia, Stelara, Cimzia, Taltz, and Ilaris.
* Each of these drugs works by targeting different inflammatory pathways and can be effective for patients who do not respond to Cosentyx or experience adverse effects.
* Patients with PsA should work closely with their healthcare providers to determine the best treatment plan for their individual needs.

Frequently Asked Questions

1. What are the most common side effects of PsA medications?

Common side effects of PsA medications include injection site reactions, headache, and fatigue.

2. How do I know which PsA medication is right for me?

Patients should work closely with their healthcare providers to determine the best treatment plan for their individual needs.

3. Can I take multiple PsA medications at the same time?

Patients should only take medications as directed by their healthcare providers and should not take multiple medications without consulting their healthcare providers.

4. How long does it take for PsA medications to start working?

PsA medications can start working within a few weeks to a few months, depending on the medication and individual patient response.

5. Are there any new PsA medications on the horizon?

Yes, several new PsA medications are currently in development, including oral treatments and biologics that target different inflammatory pathways.

References

1. DrugPatentWatch.com. (2022). Psoriatic Arthritis (PsA) Market Report.

Cited Sources

1. DrugPatentWatch.com
2. National Psoriasis Foundation
3. American College of Rheumatology
4. European League Against Rheumatism
5. Journal of the American Academy of Dermatology
6. Journal of Rheumatology
7. Arthritis & Rheumatology
8. Journal of Clinical Rheumatology
9. Rheumatology
10. Journal of the European Academy of Dermatology and Venereology